TET2 and coronary artery disorder: One such intervention may be blockade of IL‐6 receptor (Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020); our results show that those who are TET2‐CHIP+ and AgeAccelHG+ have lower risk of death or CHD with increasing copies of rs2228145, which has previously been linked to reduced IL‐6R expression levels in myeloid cells (Bick, Pirruccello, et al., 2020; Bick, Weinstock, et al., 2020).